Role of immune microenvironment in gastrointestinal stromal tumours

Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

(2016) Keith M. Kerr et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer

(2016) Y. Asano et al.   BRITISH JOURNAL OF SURGERY

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab

(2016) Sandra P. D'Angelo et al.   CLINICAL CANCER RESEARCH

PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors

(2016) Adrian M. Seifert et al.   CLINICAL CANCER RESEARCH

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

(2016) Kankana Bardhan et al.   Frontiers in Immunology

Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma

(2016) Hao Liu et al.   Scientific Reports

Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection

(2015) Shohei Eto et al.   Gastric Cancer

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients

(2015) Xinbing Sui et al.   Oncotarget

PDL1 expression is an independent prognostic factor in localized GIST

(2015) François Bertucci et al.   OncoImmunology

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

(2014) George C. Prendergast et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer

(2014) Jin Won Kim et al.   Gastric Cancer

Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors11Grant support: The Swedish Cancer Society, the Swedish research council, the Nilsson Cancer foundation, the BioCARE Strategic Cancer Research program, the Lund Medical Faculty, and FoU Landstinget Kronoberg and Södra Regionvårdnämnden.

(2014) Gottfrid Sjödahl et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor

(2013) Ronald P. DeMatteo et al.   ANNALS OF SURGERY

Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors

(2013) S. Rusakiewicz et al.   CANCER RESEARCH

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

(2012) Heikki Joensuu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

The Prognostic Significance of Tryptophanyl-tRNA Synthetase in Colorectal Cancer

(2009) A. Ghanipour et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION